ALKERMES, INC. for ALKERMES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Maintain six protected classes for depression and schizophrenia under Medicare Part D Drug pricing issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| ABIGAIL PINKELE | — |
Alcohol and Drug Abuse ALC
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings HR 695 - Department of Defense Appropriations Act 5.756 - First Step Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| ABIGAIL PINKELE | — |
Health Issues HCR
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018 PL# 114-198 - 21st Century Cures Opioid implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| ABIGAIL PINKELE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.